Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
The purpose of this study is to explore the key symptoms of individuals with systemic
 mastocytosis. Interviews of enrolled individuals will be conducted to learn about the disease
 symptoms and condition. The interview will last approximately 60 minutes and will be
 conducted by a trained interviewer, be audio-recorded (with patient consent), and all
 information provided by the patient will be treated confidentially and made anonymous so that
 it is non-identifiable. The interview may be conducted face-to-face, over the phone, or
 virtually via Skype, a free video conferencing program, depending upon the patient's
 geographic location. Patients will be compensated for their participating time.

 This is not a medication-related study, and no medication will be distributed or tested
 during this study. Participation in this study will not affect any treatment or assistance
 that a patient currently receives or may receive in the future.
Inclusion Criteria:

 -  Documented diagnosis of one of the following conditions based upon World Health
 Organization (WHO) diagnostic criteria: aggressive systemic mastocytosis (ASM),
 systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease
 (SM-AHNMD), mast cell leukemia (MCL), smoldering systemic mastocytosis (SSM), indolent
 systemic mastocytosis (ISM)

 -  Diagnosis confirmed by bone marrow biopsy

 -  Fluency in English

 -  Willingness and ability to participate in a one-hour interview

 Exclusion Criteria:

 -  A condition or situation that would interfere with participation in an interview
 (e.g., cognitive impairment or disorder, alcohol or drug abuse)

 -  Known human immunodeficiency virus or acquired immunodeficiency syndrome-related
 illness

 -  Any other prior malignancy except for the following: Adequately treated basal cell or
 squamous cell skin cancer; In situ cervical cancer; Adequately treated Stage I or II
 cancer from which the subject is currently in complete remission, or other cancer from
 which the subject has been disease-free for 2 years